Vir Biotechnology has initiated Phase III ECLIPSE program to evaluate tobevibart and elebsiran in chronic hepatitis delta patients. The program includes trials to gather data for regulatory approval, with primary focus on safety and efficacy.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing